Omicron variant remains sensitive to eight of the widely used antiviral drugs and drug candidates for the treatment of COVID-19, shows a study by scientists from the University of Kent, England and the Goethe-University Frankfurt, Germany, according to Cell Research.
Scientists who also explained why the SARS-CoV-2 Omicron variant causes less severe disease than Delta said that the drugs effective against the variant included EIDD-1931 (active metabolite of molnupiravir), ribavirin, remdesivir, favipravir, PF-07321332 (nirmatrelvir, active ingredient of paxlovid), nafamostat, camostat, and aprotinin.
